The Journal of Pain
Volume 10, Issue 8 , Pages 777-791 , August 2009

Understanding Fibromyalgia: Lessons from the Broader Pain Research Community

  • David A. Williams

      Affiliations

    • Professor of Anesthesiology, Medicine, Psychiatry and Psychology, and Associate Director, Chronic Pain and Fatigue Research Center, The University of Michigan, Ann Arbor, Michigan
    • Corresponding Author InformationAddress reprint requests to David A. Williams, Chronic Pain & Fatigue Research Center, University of Michigan, 24 Frank Lloyd Wright Drive, Lobby M, Ann Arbor, MI 48106.
    • ,
  • Daniel J. Clauw

      Affiliations

    • Professor of Anesthesiology, Medicine and Psychiatry, Associate Dean for Clinical and Translational Research, and Director, Chronic Pain and Fatigue Research Center, The University of Michigan, Ann Arbor, Michigan

References 

  1. Aaron LA, Bradley LA, Alarcon GS, Alexander RW, Triana-Alexander M, Martin MY, et al. Psychiatric diagnoses in patients with fibromyalgia are related to health care-seeking behavior rather than to illness. Arthritis Rheum. 1996;39:436–445
  2. Adelman LC, Adelman JU, Von Seggern R, Mannix LK. Venlafaxine extended release (XR) for the prophylaxis of migraine and tension-type headache: A retrospective study in a clinical setting. Headache. 2000;40:572–580
  3. Adiguzel O, Kaptanoglu E, Turgut B, Nacitarhan V. The possible effect of clinical recovery on regional cerebral blood flow deficits in fibromyalgia: A prospective study with semiquantitative SPECT. South Med J. 2004;97:651–655
  4. Adler GK, Kinsley BT, Hurwitz S, Mossey CJ, Goldenberg Dl. Reduced hypothalamic-pituitary and sympathoadrenal responses to hypoglycemia in women with fibromyalgia syndrome. Am J Med. 1999;106:534–543
  5. Alfisi S, Sigal M, Landau M. Primary fibromyalgia syndrome—A variant of depressive disorder?. Psychother Psychosom. 1989;51:156–161
  6. Anderberg UM, Marteinsdottir I, Von Knorring L. Citalopram in patients with fibromyalgia—a randomized, double-blind, placebo-controlled study. Eur J Pain. 2000;4:27–35
  7. Apkarian AV, Bushnell MC, Treede RD, Zubieta JK. Human brain mechanisms of pain perception and regulation in health and disease. Eur J Pain. 2005;9:463–484
  8. Arnold LM, Keck PE, Welge JA. Antidepressant treatment of fibromyalgia. A meta-analysis and review. Psychosomatics. 2000;41:104–113
  9. Arnold LM, Lu Y, Crofford LJ, Wohlreich M, Detke MJ, Iyengar S, et al. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum. 2004;50:2974–2984
  10. Arnold LM, Hudson JI, Hess EV, Ware AE, Fritz DA, Auchenbach MB, et al. Family study of fibromyalgia. Arthritis Rheum. 2004;50:944–952
  11. Arnold LM, Russell LJ, Diri EW, Duan WR, Young JP, Sharma U, et al. A 14-week, randomized, double-blinded, placebo-controlled monotherapy trial of pregabalin in patients with fibromyalgia. J Pain. 2008;9:792–805
  12. Arnold LM, Goldenberg Dl, Stanford SB, Lalonde JK, Sandhu HS, Keck PE, et al. Gabapentin in the treatment of fibromyalgia: A randomized, double-blind, placebo-controlled, multicenter trial. Arthritis Rheum. 2007;56:1336–1344
  13. Arroyo JF, Cohen Ml. Abnormal responses to electrocutaneous stimulation in fibromyalgia. J Rheumatol. 1993;20:1925–1931
  14. Bair MJ, Robinson Rl, Katon W, Kroenke K. Depression and pain comorbidity: A literature review. Arch Intern Med. 2003;163:2433–2445
  15. Baraniuk JN, Whalen G, Cunningham J, Clauw DJ. Cerebrospinal fluid levels of opioid peptides in fibromyalgia and chronic low back pain. BMC Musculoskelet Disord. 2004;5:48
  16. Barsky AJ, Borus JF. Functional somatic syndromes. Ann Intern. 1999;130:910–921
  17. Benjamin S, Morris S, McBeth J, Macfarlane GJ, Silman AJ. The association between chronic widespread pain and mental disorder: A population-based study. Arthritis Rheum. 2000;43:561–567
  18. Bennett RM. Pharmacological treatment of fibromyalgia. J Funct Syndromes. 2001;1:79–92
  19. Bennett RM, Kamin M, Karim R, Rosenthal N. Tramadol and acetaminophen combination tablets in the treatment of fibromyalgia pain: A double-blind, randomized, placebo-controlled study. Am J Med. 2003;114:537–545
  20. Bennett RM, Clark SR, Goldberg L, Nelson D, Bonafede RP, Porter J, et al. Aerobic fitness in patients with fibrositis. A controlled study of respiratory gas exchange and 133xenon clearance from exercising muscle. Arthritis Rheum. 1989;32:454–460
  21. Blumenthal JA, Emery CF, Madden DJ, Schniebolk S, Walsh-Riddle M, George LK, et al. Long-term effects of exercise on psychological functioning in older men and women. J Gerontol. 1991;46:352–361
  22. Bondy B, Spaeth M, Offenbaecher M, Glatzeder K, Stratz T, Schwarz M, et al. The T102C polymorphism of the 5-HT2A-receptor gene in fibromyalgia. Neurobiol Dis. 1999;6:433–439
  23. Bradley LA, Alberts KR, Alarcon GS, Alexander MT, Mountz JM, Wiegent DA, et al. Abnormal brain regional cerebral blood flow and cerebrospinal fluid levels of Substance P in patients and non-patients with fibromyalgia. Arthritis Rheum. 1996;39(9S):1109
  24. Burckhardt CS, Bjelle A. Perceived control: A comparison of women with fibromyalgia, rheumatoid arthritis, and systemic lupus erythematosus using a Swedish version of the Rheumatology Attitudes Index. Scand J Rheumatol. 1996;25:300–306
  25. Burton AK, Tillotson KM, Main CJ, Hollis S. Psychosocial predictors of outcome in acute and subchronic low back trouble. Spine. 1995;20:722–728
  26. Busch AJ, Thille P, Barber KA, Schachter Cl, Bidonde J, Collacott BK. Best practice: E-Model—prescribing physical activity and exercise for individuals with fibromyalgia. Physiother Theory Pract. 2008;24:151–166
  27. Buskila D, Sarzi-Puttini P, Ablin JN. The genetics of fibromyalgia syndrome. Pharmacogenomics. 2007;8:67–74
  28. Buskila D, Neumann L, Hazanov I, Carmi R. Familial aggregation in the fibromyalgia syndrome. Semin Arthritis Rheum. 1996;26:605–611
  29. Buskila D, Cohen H, Neumann L, Ebstein RP. An association between fibromyalgia and the dopamine D4 receptor exon III repeat polymorphism and relationship to novelty seeking personality traits. Mol Psychiatry. 2004;9:730–731
  30. Buskila D, Neumann L, Vaisberg G, Alkalay D, Wolfe F. Increased rates of fibromyalgia following cervical spine injury. A controlled study of 161 cases of traumatic injury. Arthritis Rheum. 1997;40:446–452
  31. Capaci K, Hepguler S. Comparison of the effects of amitriptyline and paroxetine in the treatment of fibromyalgia syndrome. The Pain Clinic. 2002;14:223–228
  32. Carville SF, Arendt-Nielsen S, Bliddal H, Blotman F, Branco JC, Buskila D, et al. EULAR evidence-based recommendations for the management of fibromyalgia syndrome. Ann Rheum Dis. 2008;67:536–541
  33. Clark SR. Prescribing exercise for fibromyalgia patients. Arthritis Care Res. 1994;7:221–225
  34. Clauw DJ. The pathogenesis of chronic pain and fatigue syndromes, with special reference to fibromyalgia. Med Hypotheses. 1995;44:369–378
  35. Clauw DJ. Commentary on the EULAR recommendations for the management of fibromyalgia. Nat Clin Pract Rheumatol. 2008;4:392–393
  36. Clauw DJ, Chrousos GP. Chronic pain and fatigue syndromes: Overlapping clinical and neuroendocrine features and potential pathogenic mechanisms. Neuroimmunomodulation. 1997;4:134–153
  37. Cohen H, Neumann L, Shore M, Amir M, Cassuto Y, Buskila D. Autonomic dysfunction in patients with fibromyalgia: Application of power spectral analysis of heart rate variability. Semin Arthritis Rheum. 2000;29:217–227
  38. Cohen ML, Quintner J. Fibromyalgia syndrome, a problem of tautology. Lancet. 1993;342:906–909
  39. Cook DB, Lange G, Ciccone DS, Liu WC, Steffener J, Natelson BH. Functional imaging of pain in patients with primary fibromyalgia. J Rheumatol. 2004;31:364–378
  40. Craig AD. Distribution of trigeminothalamic and spinothalamic lamina I terminations in the cat. Somatosens Mot Res. 2003;20:209–222
  41. Craig AD. Human feelings: Why are some more aware than others?. Trends Cogn Sci. 2004;8:239–241
  42. Crofford LJ, Pillemer SR, Kalogeras KT, Cash JM, Michelson D, Kling MA, et al. Hypothalamic-pituitary-adrenal axis perturbations in patients with fibromyalgia. Arthritis Rheum. 1994;37:1583–1592
  43. Crofford LJ, Rowbotham MC, Mease PJ, Russell IJ, Dworkin RH, Corbin AE, et al. Pregabalin for the treatment of fibromyalgia syndrome: Results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2005;52:1264–1273
  44. Demitrack MA, Crofford LJ. Evidence for and pathophysiologic implications of hypothalamic-pituitary-adrenal axis dysregulation in fibromyalgia and chronic fatigue syndrome. Ann NY Acad Sci. 1998;840:684–697
  45. Diatchenko L, Nackley AG, Tchivileva IE, Shabalina SA, Maixner W. Genetic architecture of human pain perception. Trends Genet. 2007;23:605–613
  46. Diatchenko L, Slade GD, Nackley AG, Bhalang K, Sigurdsson A, Belfer I, et al. Genetic basis for individual variations in pain perception and the development of a chronic pain condition. Hum Mol Genet. 2005;14:135–143
  47. Drossman DA, Li ZM, Andruzzi E, Temple RD, Talley NJ, Thompson WG, et al. U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact. Dig Dis Sci. 1993;38:1569–1580
  48. Dworkin RH, Turk DC, Wyrwich KW, Beaton D, Cleeland CS, Farrar JT, et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain. 2008;9:105–121
  49. Figueroa A, Kingsley JD, Mcmillan V, Panton LB. Resistance exercise training improves heart rate variability in women with fibromyalgia. Clin Physiol Funct Imaging. 2008;28:49–54
  50. Fishbain D. Evidence-based data on pain relief with antidepressants. Ann Med. 2000;32:305–316
  51. Fukuda K, Nisenbaum R, Stewart G, Thompson WW, Robin L, Washko RM, et al. Chronic multisymptom illness affecting Air Force veterans of the Gulf War. JAMA. 1998;280:981–988
  52. Geisser ME, Roth RS. Knowledge of and agreement with chronic pain diagnosis: Relation to affective distress, pain beliefs and coping, pain intensity, and disability. J Occup Rehabil. 1998;8:73–88
  53. Geisser ME, Robinson ME, Keefe FJ, Weiner ML. Catastrophizing, depression and the sensory, affective and evaluative aspects of chronic pain. Pain. 1994;59:79–83
  54. Geisser ME, Casey KL, Brucksch CB, Ribbens CM, Appleton BB, Crofford LJ. Perception of noxious and innocuous heat stimulation among healthy women and women with fibromyalgia: Association with mood, somatic focus, and catastrophizing. Pain. 2003;102:243–250
  55. Geisser ME, Glass JM, Rajcevska LD, Clauw DJ, Williams DA, Kileny PR, et al. A psychophysical study of auditory and pressure sensitivity in patients with fibromyalgia and healthy controls. J Pain. 2008;9:417–422
  56. Gendreau RM, Thorn MD, Gendreau JF, Kranzler JD, Ribeiro S, Gracely RH, et al. Efficacy of milnacipran in patients with fibromyalgia. J Rheumatol. 2005;32:1975–1985
  57. Gerster JC, Hadj-Djilani A. Hearing and vestibular abnormalities in primary fibrositis syndrome. J Rheumatol. 1984;11:678–680
  58. Gibson SJ, Littlejohn GO, Gorman MM, Helme RD, Granges G. Altered heat pain thresholds and cerebral event-related potentials following painful CO2 laser stimulation in subjects with fibromyalgia syndrome. Pain. 1994;58:185–193
  59. Giesecke J, Reed BD, Haefner HK, Giesecke T, Clauw DJ, Gracely RH. Quantitative sensory testing in vulvodynia patients and increased peripheral pressure pain sensitivity. Obstet Gynecol. 2004;104:126–133
  60. Giesecke T, Gracely RH, Williams DA, Geisser M, Petzke F, Clauw DJ. The relationship between depression, clinical pain, and experimental pain in a chronic pain cohort. Arthritis Rheum. 2005;52:1577–1584
  61. Giesecke T, Gracely RH, Grant MA, Nachemson A, Petzke F, Williams DA, et al. Evidence of augmented central pain processing in idiopathic chronic low back pain. Arthritis Rheum. 2004;50:613–623
  62. Giesecke T, Williams DA, Harris RE, Cupps TR, Tian X, Tian TX, et al. Subgrouping of fibromyalgia patients on the basis of pressure-pain thresholds and psychological factors. Arthritis Rheum. 2003;48:2916–2922
  63. Glass JM, Lyden A, Petzke F, Clauw D. The effect of brief exercise cessation on pain, fatigue, and mood symptom development in healthy, fit individuals. J Psychosom Res. 2004;57:391–398
  64. Goldenberg DL, Burckhardt C, Crofford L. Management of fibromyalgia syndrome. JAMA. 2004;292:2388–2395
  65. Gracely RH, Petzke F, Wolf JM, Clauw DJ. Functional magnetic resonance imaging evidence of augmented pain processing in fibromyalgia. Arthritis Rheum. 2002;46:1333–1343
  66. Gracely RH, Geisser ME, Giesecke T, Grant MA, Petzke F, Williams DA, et al. Pain catastrophizing and neural responses to pain among persons with fibromyalgia. Brain. 2004;127:835–843
  67. Granges G, Littlejohn G. Pressure pain threshold in pain-free subjects, in patients with chronic regional pain syndromes, and in patients with fibromyalgia syndrome. Arthritis Rheum. 1993;36:642–646
  68. Guedj E, Cammilleri S, Colavolpe C, De Laforte C, Niboyet J, Mundler O. Follow-up of pain processing recovery after ketamine in hyperalgesic fibromyalgia patients using brain perfusion ECD-SPECT. Eur J Nucl Med Mol Imaging. 2007;34:2115–2119
  69. Guedj E, Cammilleri S, Colavolpe C, Taieb D, De Laforte C, Niboyet J, et al. Predictive value of brain perfusion SPECT for ketamine response in hyperalgesic fibromyalgia. Eur J Nucl Med Mol Imaging. 2007;34:1274–1279
  70. Guedj E, Taieb D, Cammilleri S, Lussato D, De Laforte C, Niboyet J, et al. 99mTc-ECD brain perfusion SPECT in hyperalgesic fibromyalgia. Eur J Nucl Med Mol Imaging. 2007;34:130–134
  71. Guedj E, Cammilleri S, Niboyet J, Dupont P, Vidal E, Dropinski JP, et al. Clinical correlate of brain SPECT perfusion abnormalities in fibromyalgia. J Nucl Med. 2008;49:1798–1803
  72. Gustafsson M, Gaston-Johansson F. Pain intensity and health locus of control: A comparison of patients with fibromyalgia syndrome and rheumatoid arthritis. Patient Educ Couns. 1996;29:179–188
  73. Hamilton NA, Affleck G, Tennen H, Karlson C, Luxton D, Preacher KJ, et al. Fibromyalgia: The role of sleep in affect and in negative event reactivity and recovery. Health Psychol. 2008;27:490–497
  74. Hammett VB. Psychological changes with physical fitness training. Can Med Assoc J. 1967;96:764–769
  75. Harris RE, Clauw DJ. How do we know that the pain in fibromyalgia is “real”?. Curr Pain Headache Rep. 2006;10:403–407
  76. Harris RE, Clauw DJ, Scott DJ, Mclean SA, Gracely RH, Zubieta JK. Decreased central mu-opioid receptor availability in fibromyalgia. J Neurosci. 2007;27:10000–10006
  77. Hoffman BM, Papas RK, Chatkoff DK, Kerns RD. Meta-analysis of psychological interventions for chronic low back pain. Health Psychol. 2007;26:1–9
  78. Holman AJ, Myers RR. A randomized, double-blind, placebo-controlled trial of pramipexole, a dopamine agonist, in patients with fibromyalgia receiving concomitant medications. Arthritis Rheum. 2005;52:2495–2505
  79. Hudson JI, Hudson MS, Pliner LF, Goldenberg DL, Pope HG. Fibromyalgia and major affective disorder: A controlled phenomenology and family history study. Am J Psychiatry. 1985;142:441–446
  80. Hudson JI, Goldenberg DL, Pope HG, Keck PE, Schlesinger L. Comorbidity of fibromyalgia with medical and psychiatric disorders. A J Med. 1993;92:363–367
  81. Janal MN. Pain sensitivity, exercise and stoicism. J R Soc Med. 1996;89:376–381
  82. Jensen MP, Turner JA, Romano JM. Changes after multidisciplinary pain treatment in patient pain beliefs and coping are associated with concurrent changes in patient functioning. Pain. 2007;131:38–47
  83. Jones SL. Descending noradrenergic influences on pain. Prog Brain Res. 1991;88:381–394
  84. Julien N, Goffaux P, Arsenault L, Marchand S. Widespread pain in fibromyalgia is related to a deficit of endogenous pain inhibition. Pain. 2005;114:295–302
  85. Kato K, Sullivan PF, Evengard B, Pedersen NL. Chronic widespread pain and its comorbidities: A population-based study. Arch Intern Med. 2006;166:1649–1654
  86. Kato K, Sullivan PF, Evengard B, Pedersen NL. Importance of genetic influences on chronic widespread pain. Arthritis Rheum. 2006;54:1682–1686
  87. Kato K, Sullivan PF, Evengard B, Pedersen NL. A population-based twin study of functional somatic syndromes. Psychol Med. 2009;39:497–505
  88. Keefe FJ, Brown GK, Wallston KA, Caldwell DS. Coping with rheumatoid arthritis pain: Catastrophizing as a maladaptive strategy. Pain. 1989;37:51–56
  89. Khan AA, Khan A, Harezlak J, Tu W, Kroenke K. Somatic symptoms in primary care: Etiology and outcome. Psychosomatics. 2003;44:471–478
  90. Kosek E, Hansson P. Modulatory influence on somatosensory perception from vibration and heterotopic noxious conditioning stimulation (HNCS) in fibromyalgia patients and healthy subjects. Pain. 1997;70:41–51
  91. Kosek E, Ekholm J, Hansson P. Sensory dysfunction in fibromyalgia patients with implications for pathogenic mechanisms. Pain. 1996;68:375–383
  92. Kuraishi Y, Hirota N, Satoh M, Takagi H. Antinociceptive effects of intrathecal opioids, noradrenaline and serotonin in rats: Mechanical and thermal algesic tests. Brain Res. 1985;326:168–171
  93. Kwiatek R, Barnden L, Tedman R, Jarrett R, Chew J, Rowe C, et al. Regional cerebral blood flow in fibromyalgia: Single-photon-emission computed tomography evidence of reduction in the pontine tegmentum and thalami. Arthritis Rheum. 2000;43:2823–2833
  94. Lautenbacher S, Rollman GB. Possible deficiencies of pain modulation in fibromyalgia. Clin J Pain. 1997;13:189–196
  95. Le Bars D, Villanueva L, Bouhassira D, Willer JC: Diffuse noxious inhibitory controls (DNIC) in animals and in man Patol Fiziol Eksp ter 55–65,1992
  96. Leffler AS, Hansson P, Kosek E. Somatosensory perception in a remote pain-free area and function of diffuse noxious inhibitory controls (DNIC) in patients suffering from long-term trapezius myalgia. Eur J Pain. 2002;6:149–159
  97. Maixner W, Fillingim R, Booker D, Sigurdsson A. Sensitivity of patients with painful temporomandibular disorders to experimentally evoked pain. Pain. 1995;63:341–351
  98. Martinez-Lavin M, Hermosillo AG, Rosas M, Soto ME. Circadian studies of autonomic nervous balance in patients with fibromyalgia: A heart rate variability analysis. Arthrit Rheumat. 1998;41:1966–1971
  99. Mayer EA, Raybould HE. Role of visceral afferent mechanisms in functional bowel disorders. Gastroenterology. 1990;99:1688–1704
  100. McBeth J, Jones K. Epidemiology of chronic musculoskeletal pain. Best Pract Res Clin Rheumatol. 2007;21:403–425
  101. McBeth J, Silman AJ, Gupta A, Chiu YH, Ray D, Morriss R, et al. Moderation of psychosocial risk factors through dysfunction of the hypothalamic-pituitary-adrenal stress axis in the onset of chronic widespread musculoskeletal pain: Findings of a population-based prospective cohort study. Arthritis Rheum. 2007;56:360–371
  102. McCann IL, Holmes DS. Influence of aerobic exercise on depression. J Pers Soc Psychol. 1984;46:1142–1147
  103. Mccarberg B, Wolf J, Oliver K, Fakhry F, Walen H, Cronan T. The relationship between health locus of control and well-being in fibromyalgia patients. J Pain. 2002;3(2):14
  104. Mcdermid AJ, Rollman GB, Mccain GA. Generalized hypervigilance in fibromyalgia: Evidence of perceptual amplification. Pain. 1996;66:133–144
  105. McGavin CR, Gupta SP, Lloyd EL, Mchardy GJ. Physical rehabilitation for the chronic bronchitic: Results of a controlled trial of exercises in the home. Thorax. 1977;32:307–311
  106. McLean SA, Williams DA, Harris RE, Kop WJ, Groner KH, Ambrose K, et al. Momentary relationship between cortisol secretion and symptoms in patients with fibromyalgia. Arthritis Rheum. 2005;52:3660–3669
  107. McLean SA, Williams DA, Stein PK, Harris RE, Lyden AK, Whalen G, et al. Cerebrospinal fluid corticotropin-releasing factor concentration is associated with pain but not fatigue symptoms in patients with fibromyalgia. Neuropsychopharmacology. 2006;31:2776–2782
  108. Mease P, Arnold LM, Bennett R, Boonen A, Buskila D, Carville S, et al. Fibromyalgia syndrome. J Rheumatol. 2007;34:1415–1425
  109. Mease PJ, Russell IJ, Arnold LM, Florian H, Young JP, Martin SA, et al. A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia. J Rheumatol. 2008;35:502–514
  110. Mease PJ, Arnold LM, Crofford LJ, Williams DA, Russell IJ, Humphrey L, et al. Identifying the clinical domains of fibromyalgia: Contributions from clinician and patient Delphi exercises. Arthritis Rheum. 2008;59:952–960
  111. Meldrum Ml. A capsule history of pain management. JAMA. 2003;290:2470–2475
  112. Minor MA, Hewett JE, Webel RR, Anderson SK, Kay DR. Efficacy of physical conditioning exercise in patients with rheumatoid arthritis and osteoarthritis. Arthritis Rheum. 1989;32:1396–1405
  113. Moldofsky H, Scarisbrick P, England R, Smythe H. Musculosketal symptoms and non-REM sleep disturbance in patients with “fibrositis syndrome” and healthy subjects. Psychosom Med. 1975;37:341–351
  114. Morley S, Eccleston C, Williams A. Systematic review and meta-analysis of randomized controlled trials of cognitive behaviour therapy and behaviour therapy for chronic pain in adults, excluding headache. Pain. 1999;80:1–13
  115. Moshiree B, Price DD, Robinson ME, Gaible R, Verne GN. Thermal and visceral hypersensitivity in irritable bowel syndrome patients with and without fibromyalgia. Clin J Pain. 2007;23:323–330
  116. Mountz JM, Bradley LA, Modell JG, Alexander RW, Triana-Alexander M, Aaron LA, et al. Fibromyalgia in women. Abnormalities of regional cerebral blood flow in the thalamus and the caudate nucleus are associated with low pain threshold levels. Arthritis Rheum. 1995;38:926–938
  117. Naliboff BD, Derbyshire SW, Munakata J, Berman S, Mandelkern M, Chang L, et al. Cerebral activation in patients with irritable bowel syndrome and control subjects during rectosigmoid stimulation. Psychosom Med. 2001;63:365–375
  118. Norregaard J, Volkmann H, Danneskiold-Samsoe B. A randomized controlled trial of citalopram in the treatment of fibromyalgia. Pain. 1995;61:445–449
  119. O'malley PG, Balden E, Tomkins G, Santoro J, Kroenke K, Jackson JL. Treatment of fibromyalgia with antidepressants. A meta-analysis. J Gen Intern Med. 2000;15:659–666
  120. Offenbaecher M, Bondy B, De Jonge S, Glatzeder K, Kruger M, Schoeps P, et al. Possible association of fibromyalgia with a polymorphism in the serotonin transporter gene regulatory region. Arthritis Rheum. 1999;42:2482–2488
  121. Pastor MA, Salas E, Lopez S, Rodriguez J, Sanchez S, Pascual E. Patients' beliefs about their lack of pain control in primary fibromyalgia syndrome. B J Rheumatol. 1993;32:484–489
  122. Petzke F, Gracely RH, Park KM, Ambrose K, Clauw DJ. What do tender points measure? Influence of distress on 4 measures of tenderness. J Rheumatol. 2003;30:567–574
  123. Petzke F, Clauw DJ, Ambrose K, Khine A, Gracely RH. Increased pain sensitivity in fibromyalgia: Effects of stimulus type and mode of presentation. Pain. 2003;105:403–413
  124. Petzke F, Harris RE, Williams DA, Clauw DJ, Gracely RH. Differences in unpleasantness induced by experimental pressure between patients with fibromyalgia and healthy controls. Eur J Pain. 2005;9:325–335
  125. Petzke F, Khine A, Williams D, Groner K, Clauw DJ, Gracely RH. Dolorimetry performed at 3 paired tender points highly predicts overall tenderness. J Rheumatol. 2001;28:2568–2569
  126. Price DD, Staud R, Robinson ME, Mauderli AP, Cannon R, Vierck CJ. Enhanced temporal summation of second pain and its central modulation in fibromyalgia patients. Pain. 2002;99:49–59
  127. Qiao ZG, Vaeroy H, Morkrid L. Electrodermal and microcirculatory activity in patients with fibromyalgia during baseline, acoustic stimulation and cold pressor tests. J Rheumatol. 1991;18:1383–1389
  128. Raphael KG, Natelson BH, Janal MN, Nayak S. A community-based survey of fibromyalgia-like pain complaints following the World Trade Center terrorist attacks. Pain. 2002;100:131–139
  129. Ren K, Dubner R. NMDA receptor antagonists attenuate mechanical hyperalgesia in rats with unilateral inflammation of the hindpaw. Neurosci Lett. 1993;163:22–26
  130. Rossy LA, Buckelew SP, Dorr N, Hagglund KJ, Thayer JF, Mcintosh MJ, et al. A meta-analysis of fibromyalgia treatment interventions. Ann Behav Med. 1999;21:180–191
  131. Russell IJ, Vaeroy H, Javors M, Nyberg F. Cerebrospinal fluid biogenic amine metabolites in fibromyalgia/fibrositis syndrome and rheumatoid arthritis. Arthritis Rheum. 1992;35:550–556
  132. Russell IJ, Michaelek JE, Ziao Y, Haynes W, Vertiz R, Lawrence RA. Therapy with a central alpha 2-adrenergic agonist (tizanidine) decreases cerebrospinal fluid substance P, and may reduce serum hyaluronic acid as it improves the clinical symptoms of the fibromyalgia syndrome. Arthritis Rheum. 2002;46(9):S614
  133. Russell IJ, Orr MD, Littman B, Vipraio GA, Alboukrek D, Michalek JE, et al. Elevated cerebrospinal fluid levels of substance P in patients with the fibromyalgia syndrome. Arthritis Rheum. 1994;37:1593–1601
  134. Sapolsky RM. Why stress is bad for your brain. Science. 1996;273:749–750
  135. Sarchielli P, Di Filippo M, Nardi K, Calabresi P. Sensitization, glutamate, and the link between migraine and fibromyalgia. Curr Pain Headache Rep. 2007;11:343–351
  136. Scharf MB, Baumann M, Berkowitz DV. The effects of sodium oxybate on clinical symptoms and sleep patterns in patients with fibromyalgia. J Rheumatol. 2003;30:1070–1074
  137. Sjostrom S, Tamsen A, Hartvig P, Folkesson R, Terenius L. Cerebrospinal fluid concentrations of substance P and (met)enkephalin-Arg6-Phe7 during surgery and patient-controlled analgesia. Anesth Analg. 1988;67:976–981
  138. Smythe HA, Moldofsky H. Two contributions to understanding of the “fibrositis” syndrome. Bulletin on the Rheumatic Diseases. 1977;28:928–931
  139. Sonstroem RJ. Exercise and self-esteem. Exerc Sport Sci Rev. 1984;21:329–337
  140. Staud R, Vierck CJ, Cannon RL, Mauderli AP, Price DD. Abnormal sensitization and temporal summation of second pain (wind-up) in patients with fibromyalgia syndrome. Pain. 2001;91:165–175
  141. Staud R, Carl KE, Vierck CJ, Price DD, Robinson ME, Cannon RL, et al. Repetitive muscle stimuli result in enhanced wind-up of fibromyalgia patients. Arthritis Rheum. 2001;44:S395–S395
  142. Stein PK, Domitrovich PP, Ambrose K, Lyden A, Fine M, Gracely RH, et al. Sex effects on heart rate variability in fibromyalgia and Gulf War illness. Arthritis Rheum. 2004;51:700–708
  143. Stroud MW, Thorn BE, Jensen MP, Boothby JI. The relation between pain beliefs, negative thoughts, and psychosocial functioning in chronic pain patients. Pain. 2000;84:347–352
  144. Sullivan MJ, Stanish W, Waite H, Sullivan M, Tripp DA. Catastrophizing, pain, and disability in patients with soft-tissue injuries. Pain. 1998;77:253–260
  145. Tracey I. Imaging pain. Br J Anaesth. 2008;101:32–39
  146. Tracey I, Mantyh PW. The cerebral signature for pain perception and its modulation. Neuron. 2007;55:377–391
  147. Tugwell P, Boers M, Brooks P, Simon L, Strand V, Idzerda L. OMERACT: An international initiative to improve outcome measurement in rheumatology. Trials. 2007;8(38):
  148. Turk DC. The Potential of Treatment Matching for Subgroups of Patients With Chronic Pain: Lumping Versus Splitting. Clin J Pain. 2005;21:44–55
  149. Turk DC, Dworkin RH, Revicki D, Harding G, Burke LB, Cella D, et al. Identifying important outcome domains for chronic pain clinical trials: An IMMPACT survey of people with pain. Pain. 2008;137:276–285
  150. Turner JA, Jensen MP, Romano JM. Do beliefs, coping, and catastrophizing independently predict functioning in patients with chronic pain?. Pain. 2000;85:115–125
  151. Vaeroy H, Helle R, Forre O, Kass E, Terenius L. Elevated CSF levels of substance P and high incidence of Raynaud phenomenon in patients with fibromyalgia: New features for diagnosis. Pain. 1988;32:21–26
  152. Vitton O, Gendreau M, Gendreau J, Kranzler J, Rao SG. A double-blind placebo-controlled trial of milnacipran in the treatment of fibromyalgia. Hum Psychopharmacol. 2004;19(Suppl 1):27–35
  153. Welin M, Bragee B, Nyberg F, Kristiansson M. Elevated Substance P levels are contrasted by a decrease in met-enkephalin-arg-phe levels in CSF from fibromyalgia patients. Journal of Musculoskeletal Pain. 1995;3:4
  154. Wessely S, Chalder T, Hirsch S, Wallace P, Wright D. Psychological symptoms, somatic symptoms, and psychiatric disorder in chronic fatigue and chronic fatigue syndrome: A prospective study in the primary care setting. Am J Psychiatry. 1996;153:1050–1059
  155. White KP, Nielson WR, Harth M, Ostbye T, Speechley M. Does the label “fibromyalgia” alter health status, function, and health service utilization? A prospective, within-group comparison in a community cohort of adults with chronic widespread pain. Arthritis Rheum. 2002;47:260–265
  156. Wiffen P, Collins S, McQuay H, Carroll D, Jadad A, Moore A. Anticonvulsant drugs for acute and chronic pain. Cochrane Database Syst Rev. 2000;(3):CD001133
  157. Wigers SH, Stiles TC, Vogel PA. Effects of aerobic exercise versus stress management treatment in fibromyalgia. A 4.5 year prospective study. Scand J Rheumatol. 1996;25:77–86
  158. Williams DA. Psychological and behavioral therapies in fibromyagia and related syndromes. Baillieres Best Pract Res Clin Rheumatol. 2003;17:649–665
  159. Williams DA, Keefe FJ. Pain beliefs and the use of cognitive-behavioral coping strategies. Pain. 1991;46:185–190
  160. Williams DA, Robinson ME, Geisser ME. Pain beliefs: Assessment and utility. Pain. 1994;59:71–78
  161. Williams DA, Brown SC, Clauw DJ, Gendreau RM. Self-reported symptoms before and after September 11 in patients with fibromyalgia. JAMA. 2003;289:1637–1638
  162. Williams DA, Cary MA, Groner KH, Chaplin W, Glazer LJ, Rodriguez AM, et al. Improving physical functional status in patients with fibromyalgia: A brief cognitive behavioral intervention. J Rheumatol. 2002;29:1280–1286
  163. Willis WD. Central plastic responses to pain. In:  Gebhart GF,  Hammond DL,  Jensen TS editor. Proceedings of the 7th World Congress on Pain. 21 Edition. Seattle, WA: International Association for the Study of Pain (IASP); 1994;p. 301–324
  164. Wolfe F. The relation between tender points and fibromyalgia symptom variables: Evidence that fibromyalgia is not a discrete disorder in the clinic. Ann Rheum Dis. 1997;56:268–271
  165. Wolfe F, Ross K, Anderson J, Russell IJ. Aspects of fibromyalgia in the general population: Sex, pain threshold, and fibromyalgia symptoms. J Rheumatol. 1995;22:151–156
  166. Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, et al. The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum. 1990;33:160–172
  167. Wood PB, Patterson JC, Sunderland JJ, Tainter KH, Glabus MF, Lilien DI. Reduced presynaptic dopamine activity in fibromyalgia syndrome demonstrated with positron emission tomography: A pilot study. J Pain. 2007;8:51–58
  168. Wood PB, Schweinhardt P, Jaeger E, Dagher A, Hakyemez H, Rabiner EA, et al. Fibromyalgia patients show an abnormal dopamine response to pain. Eur J Neurosci. 2007;25:3576–3582
  169. Woolf CJ. Windup and central sensitization are not equivalent. Pain. 1996;66:105–108
  170. Woolf CJ. Pain: Moving from symptom control toward mechanism-specific pharmacologic management. Ann Intern Med. 2004;140:441–451
  171. Woolf CJ, Thompson SW. The induction and maintenance of central sensitization is dependent on N-methyl-D-aspartic acid receptor activation; implications for the treatment of post-injury pain hypersensitivity states. Pain. 1991;44:293–299
  172. World Health Organization. International Classification of Functioning. Disability and Health: Geneva; 2001;
  173. Xu XJ, Dalsgaard CJ, Wiesenfeld-Hallin Z. Spinal substance P and N-methyl-D-aspartate receptors are coactivated in the induction of central sensitization of the nociceptive flexor reflex. Neuroscience. 1992;51:641–648
  174. Yunus M, Masi AT, Calabro JJ, Miller KA, Feigenbaum SL. Primary fibromyalgia (fibrositis): Clinical study of 50 patients with matched normal controls. Semin Arthritis Rheum. 1981;11:151–171
  175. Yunus MB. Central sensitivity syndromes: A new paradigm and group nosology for fibromyalgia and overlapping conditions, and the related issue of disease versus illness. Semin Arthritis Rheum. 2008;37:339–352
  176. Yunus MB, Young CS, Saeed AS, Aldag JC. Positron Emission Tomography (PET) imaging of the brain in fibromyalgia syndrome (FMS). Arthritis Rheum. 1997;40:S188
  177. Yunus MB, Dailey JW, Aldag JC, Masi AT, Jobe PC. Plasma tryptophan and other amino acids in primary fibromyalgia: A controlled study. J Rheumatol. 1992;19:90–94

 Editor's Note: This article is 1 in a series of invited Critical Review articles designed to celebrate The Journal of Pain's 10th year anniversary of publication.

 Supported in part by grant numbers R01-AR050044 (NIAMS/NIH), AR053207 (NIAMS/NIH), U01AR55069 (NIAMS/NIH) and DAMD 17-00-2-0018 (Department of Defense).

PII: S1526-5900(09)00548-3

doi: 10.1016/j.jpain.2009.06.001

The Journal of Pain
Volume 10, Issue 8 , Pages 777-791 , August 2009

Article Tools